Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 6/20 | 0.60 |
| ▸ | HTR2A | P28223 | 6/20 | 0.60 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.55 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.42 |
| ▸ | DRD1 | P21728 | 1/20 | 0.42 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | CASR | P41180 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8120558 | 0.93 | SIGMAR1 (0.59) | HRH1HTR2ASIGMAR1TAAR1CYP19A1 | |
| SCHEMBL7199600 | 0.91 | SIGMAR1 (0.57) | HRH1HTR2ASIGMAR1TAAR1CYP19A1 | |
| SCHEMBL2172475 | 0.84 | HRH1 (0.56) | HRH1HTR2ASIGMAR1TAAR1KCNH2 | |
| SCHEMBL9073997 | 0.84 | HRH1 (0.71) | HRH1HTR2ASIGMAR1TAAR1CYP19A1 | |
| SCHEMBL30171026 | 0.82 | HRH1 (0.54) | HRH1HTR2ASIGMAR1TAAR1KCNH2 | |
| SCHEMBL8907610 | 0.81 | RIPK1 (0.53) | LMNA | |
| SCHEMBL2710461 | 0.81 | HTR2A (0.40) | HRH1HTR2ASIGMAR1TAAR1 | |
| SCHEMBL16426377 | 0.79 | HTR2A (0.39) | HRH1HTR2ASIGMAR1TAAR1 | |
| SCHEMBL3618081 | 0.79 | RIPK1 (0.53) | HRH1HTR2ASIGMAR1TAAR1 | |
| SCHEMBL5864161 | 0.79 | CYP19A1 (0.47) | HRH1HTR2ACYP19A1HTR1AADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011143444-A2 | DIPHENYLBUTYPIPERIDINE AUTOPHAGY INDUCERS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2011-11-17 | — | — | WO | disclosed |
| US-7488755-B2 | Derivatives of glycinergic R(+)-2-amino-3-hydroxypropanoic acid | PRESTWICK PHARMACEUTICALS, INC. (US) | 2009-02-10 | — | — | US | disclosed |
| US-20050261372-A1 | Derivatives of glycinergic r(+)-2-amino-3-hydroxypropanoic acid | ORAPHARMA, INC. | 2005-11-24 | — | — | US | disclosed |
| EP-1529030-A2 | DERIVATIVES OF GLYCINERGIC R(+)-2-AMINO-3-HYDROXYPROPANOIC ACID | Prestwick Pharmaceuticals, Inc. (US) | 2005-05-11 | — | — | EP | disclosed |
| WO-2004016580-A2 | DERIVATIVES OF GLYCINERGIC R(+)-2-AMINO-3-HYDROXYPROPANOIC ACID | PRESTWICK PHARMACEUTICALS, INC. (US) | 2004-02-26 | — | — | WO | disclosed |
| US-6599940-B2 | Neurotransmitters | GEORGETOWN UNIVERSITY | 2003-07-29 | — | — | US | disclosed |
| US-20020147362-A1 | Synthesis of 2-Hydroxymethylglutamic acid and congeners thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-10-10 | — | — | US | disclosed |
| WO-2002022622-A2 | SYNTHESIS OF 2-HYDROXYMETHYLGLUTAMIC ACID AND CONGENERS THEREOF | GEORGETOWN UNIVERSITY (US) | 2002-03-21 | — | — | WO | disclosed |
| US-5932573-A | Substituted quinolines and isoquinolines as calcium channel blockers, their preparation and the use thereof | WARNER-LAMBERT COMPANY (US) | 1999-08-03 | — | — | US | disclosed |
| EP-0656345-B1 | Aspartic acid derivatives or homologues thereof and their use in the treatment of neurological diseases | UNIV PASTEUR (FR) | 1999-03-10 | — | — | EP | disclosed |
| US-5767129-A | TREATING CEREBROVASCULAR DISORDERS, PAIN, CEREBRAL ISCHEMIA | WARNER-LAMBERT COMPANY (US) | 1998-06-16 | — | — | US | disclosed |
| US-5739164-A | BLOCK METABOTROPIC GLUTAMATE RECEPTORS | ELI LILLY AND COMPANY (US) | 1998-04-14 | — | — | US | disclosed |
| US-5589501-A | TREATMENT OF NEUROLOGICAL DISEASES, ANTIPSYCHOTIC, ANTICONVULSANT, ANALGESIC AND ANTIEMETIC AGENT | ELI LILLY AND COMPANY (US) | 1996-12-31 | — | — | US | disclosed |
| EP-0656345-A1 | Aspartic acid derivatives or homologues thereof and their use in the treatment of neurological diseases | Université Louis Pasteur (FR) | 1995-06-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261372-A1 | Derivatives of glycinergic r(+)-2-amino-3-hydroxypropanoic acid | GLRA3, GLRA1, GLRA2 | HRH1 100/4885HTR2A 70/4885SIGMAR1 1039/4885 |
| US-20020147362-A1 | Synthesis of 2-Hydroxymethylglutamic acid and congeners thereof | OGDH, FPGS, GGCT | HRH1 3892/4885HTR2A 1050/4885SIGMAR1 4876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.